Khiron Life Sciences (Khiron Life Sciences) Cash And Cash Equivalents : $1.45 Mil (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Khiron Life Sciences Cash And Cash Equivalents?

Khiron Life Sciences's quarterly cash and cash equivalents increased from Mar. 2022 ($4.05 Mil) to Jun. 2022 ($4.54 Mil) but then stayed the same from Jun. 2022 ($4.54 Mil) to Sep. 2022 ($1.45 Mil).

Khiron Life Sciences's annual cash and cash equivalents increased from Dec. 2019 ($7.10 Mil) to Dec. 2020 ($16.90 Mil) but then declined from Dec. 2020 ($16.90 Mil) to Dec. 2021 ($6.97 Mil).

Khiron Life Sciences Cash And Cash Equivalents Historical Data

The historical data trend for Khiron Life Sciences's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Khiron Life Sciences Cash And Cash Equivalents Chart

Khiron Life Sciences Annual Data

Trend

May12

May13

May14

May15

May16

May17

Dec18

Dec19

Dec20

Dec21

Cash And Cash Equivalents

Get a 7-Day Free Trial

11.17

7.10

16.90

6.97

Khiron Life Sciences Quarterly Data
	Nov17	Feb18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash And Cash Equivalents	Get a 7-Day Free Trial															12.17	6.97	4.05	4.54	1.45

Khiron Life Sciences Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Khiron Life Sciences (OTCPK:KHRWF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Khiron Life Sciences Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Khiron Life Sciences's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Khiron Life Sciences (Khiron Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Khiron Life Sciences Corp (OTCPK:KHRWF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5

Website

https://www.khiron.ca

Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.